Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07184203
Recruiting Not applicable

Comparison Between Continuous and Pulse Itraconazole in Tinea Capitis in Children

NCT07184203 · tracked via the Priya Life Science Egypt tracker
Sponsor
Alexandria University
Phase
Not applicable
Started
2025-03-09
Last updated
2025-09-19

Condition(s) studied

Tinea Capitis

Investigational drug(s) / intervention(s)

Itraconazole (ITZ) →

Itraconazole (ITZ): therapy for tinea capitis orally

Study summary

A study to compare the efficacy of daily therapy versus pulse therapy of oral itraconazole in the treatment of tinea capitis in children based on clinical, mycological and dermoscopic evaluation.

Eligibility

Sex
ALL
Min age
5 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: • Tinea capitis patients with ages ranging from 5 to 18 year Exclusion Criteria: * Patients with contraindications to itraconazole * Patients with associated scalp disease. * Patients weighing less than 20 Kg.

Primary outcome measure(s)

  • improvement of tinea capitis — 3 months
    cure of tinea capitis

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine Alexandria Egypt Recruiting

More Alexandria University trials in Egypt

VEXUS and Assessment of Dry Weight of Patients on Hemodialysis Recruiting
Effect of Dexmedetomidine Supplementation to General Anaesthesia in Paediatric Transcatheter Closure of Atrial Septal Defect Recruiting
Patient-Specific Guides for Gap Pediatric Arthroplasty Active, not recruiting
Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy Recruiting
Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin Recruiting

Other trials for the same condition

Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working Active, not recruiting
Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07184203 on ClinicalTrials.gov ↗ ← All trials in Egypt